FDA en­cour­ages in­clud­ing in­cur­able can­cer pa­tients in tri­als, re­gard­less of pri­or ther­a­pies

The FDA on Thurs­day called to in­clude those with in­cur­able can­cers (when there is no po­ten­tial for cure or for pro­longed/near nor­mal sur­vival) in ap­pro­pri­ate clin­i­cal tri­als, re­gard­less of whether they have re­ceived ex­ist­ing al­ter­na­tive treat­ments.

His­tor­i­cal­ly, many can­cer clin­i­cal tri­als have re­quired that par­tic­i­pat­ing pa­tients pre­vi­ous­ly re­ceived mul­ti­ple ther­a­pies, ac­cord­ing to Richard Paz­dur, di­rec­tor of the FDA’s On­col­o­gy Cen­ter of Ex­cel­lence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER